[1] Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov 2012;11(5):367-83
[2] Artenstein AW, Opal SM. Proprotein convertases in health and disease. N Engl J Med 2011;365(26):2507-18
[3] Couture F, Kwiatkowska A, Dory YL, Day R. Therapeutic uses of furin and its inhibitors: a patent review. Expert Opin Ther Pat. 2015 Apr;25(4):379-96. doi: 0.1517/13543776.2014.1000303. Epub 2015 Jan 7. PMID: 25563687.
[4] Villefranc JA, Nicoli S, Bentley K, Jeltsch M, Zarkada G, Moore JC, Gerhardt H, Alitalo K, Lawson ND. A truncation allele in vascular endothelial growth factor c reveals distinct modes of signaling during lymphatic and vascular development. Development. 2013 Apr;140(7):1497-506. doi: 10.1242/dev.084152. Epub 2013 Mar 5. PMID: 23462469; PMCID: PMC3596992.
[5] Zhao J, Xu W, Ross JW, Walters EM, Butler SP, Whyte JJ, Kelso L, Fatemi M, Vanderslice NC, Giroux K, Spate LD, Samuel MS, Murphy CN, Wells KD, Masiello NC, Prather RS, Velander WH. Engineering protein processing of the mammary gland to produce abundant hemophilia B therapy in milk. Sci Rep. 2015 Sep 21;5:14176. doi: 10.1038/srep14176. PMID: 26387706; PMCID: PMC4585688.
[6] Preininger, A.; Schlokat, U.; Mohr, G.; Himmelspach, M.; Stichler, V.; Kyd-Rebenburg, A.; Plaimauer, B.; Turecek, P.L.; Schwarz, H.P.; Wernhart, W.; et al. Strategies for recombinant Furin employment in a biotechnological process: Complete target protein precursor cleavage. Cytotechnology 1999, 30, 1–16. [CrossRef]
[7] Plaimauer, B.; Mohr, G.; Wernhart, W.; Himmelspach, M.; Dorner, F.; Schlokat, U. ‘Shed’ furin: Mapping of the cleavage determinants and identification of its C-terminus. Biochem J. 2001, 354, 689–695. [CrossRef] [PubMed]
[8] Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E (February 2020). "The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade". Antiviral Research. 176: 104742. doi:10.1016/j.antiviral.2020.104742. PMC 7114094. PMID 32057769.
[9] Hoffmann, Markus (2020). "A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells". Molecular Cell. 78 (4): 779–784.e5. doi:10.1016/j.molcel.2020.04.022. PMC 7194065. PMID 32362314.
[10] Jeroen Declercq, John W.M. Creemers, in Handbook of Proteolytic Enzymes (Third Edition), 2013
[11] Dahms, S. O. et al. X-ray Structures of Human Furin in Complex with Competitive Inhibitors. ACS Chem. Biol. 140408095720006 (2014). doi:10.1021/cb500087x
[12] Xia, S., Lan, Q., Su, S. et al. The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin. Sig Transduct Target Ther 5, 92 (2020). https://doi.org/10.1038/s41392-020-0184-0
[13] Vankadari N. Structure of Furin Protease Binding to SARS-CoV‑2 Spike Glycoprotein and Implications for Potential Targets and Virulence. J. Phys. Chem. Lett. 2020, 11, 6655−6663
[14] Park, J.E., Li, K., Barlan, A., Fehr, A.R., Perlman, S., McCray, P.B., Jr., and Gallagher, T. (2016). Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism. Proc. Natl. Acad. Sci. USA 113, 12262–12267.
[15] Wang, Q., Qiu, Y., Li, J.Y., Zhou, Z.J., Liao, C.H., and Ge, X.Y. (2020a). A unique protease cleavage site predicted in the spike protein of the novel pneumonia coronavirus (2019-nCoV) potentially related to viral transmissibility. Virol. Sin. 35, 337–339.
[16] Ya-Wen Cheng, Tai-Ling Chao, Chiao-Ling Li, Mu-Fan Chiu, Han-Chieh Kao, Sheng-Han Wang, Yu-Hao Pang, Chih-Hui Lin, Ya-Min Tsai, Wen-Hau Lee, Mi-Hua Tao, Tung-Ching Ho, Ping-Yi Wu, Li-Ting Jang, Pei-Jer Chen, Sui-Yuan Chang, and Shiou-Hwei Yeh. Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects. Cell Reports 33, 108254, October 13, 2020
[17] Hoffmann, M., Kleine-Weber, H., Schroeder, S., Kr€uger, N., Herrler, T., Erichsen, S., Schiergens, T.S., Herrler, G., Wu, N.H., Nitsche, A., et al. (2020b). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280.e8.
[18] Yi Ming & Liu Qiang. Involvement of Spike Protein, Furin, and ACE2 in SARS-CoV-2-Related Cardiovascular Complications. SN Comprehensive Clinical Medicine (2020) 2:1103–1108
[19] Adu-Agyeiwaah Y, Grant MB, Obukhov AG. The Potential Role of Osteopontin and Furin in Worsening Disease Outcomes in COVID-19 Patients with Pre-Existing Diabetes. Cells. 2020 Nov 23;9(11):2528. doi: 10.3390/cells9112528. PMID: 33238570; PMCID: PMC7700577.
[20] Dahms SO, Arciniega M, Steinmetzer T, Huber R, Than ME. Structure of the unliganded form of the proprotein convertase furin suggests activation by a substrate-induced mechanism. Proc Natl Acad Sci U S A. 2016 Oct 4;113(40):11196-11201. doi: 10.1073/pnas.1613630113. Epub 2016 Sep 19. PMID: 27647913; PMCID: PMC5056075.
Coutard, B., Valle, C., de Lamballerie, X., Canard, B., Seidah, N.G., and Decroly, E. (2020). The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 176, 104742.
[21] Seidah, N.G., and Prat, A. (2012). The biology and therapeutic targeting of the proprotein convertases. Nat. Rev. Drug Discov. 11, 367–383.
[22] Coutard, B., Valle, C., de Lamballerie, X., Canard, B., Seidah, N.G., and Decroly, E. (2020). The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 176, 104742.
[23] Sheng C, Ji H, Miao Z, Che X, Yao J, Wang W, Dong G, Guo W, Lü J, Zhang W. Homology modeling and molecular dynamics simulation of N-myristoyltransferase from protozoan parasites: active site characterization and insights into rational inhibitor design. J Comput Aided Mol Des. 2009, 23(6): 75-89
[24] Macindoe G, Mavridis L, Venkatraman V, Devignes MD, Ritchie DW. HexServer: an FFT-based protein docking server powered by graphics processors. Nucleic Acids Res. 2010, 38 -9
[25] Abdelouahab C, Abderrahmane B (2008) Docking Efficiency Comparison of Surflex, a Commercial Package and Arguslab, a Licensable Freeware. J Comput Sci Syst Biol. 2008, 1: 081-086. [DOI:10.4172/jcsb.1000007].
[26] Function DW, Ritchie D, Vajda S. Accelerating Protein-Protein Docking Correlations Using A Six-Dimensional Analytic FFT Generating, Bioinformatics, 2008, 24(17), 1865-1873
[27] Tetko IV; Gasteiger J, Todeschini R, Mauri A, Livingstone D, Ertl P, Palyulin VA, Radchenko EV, Zefirov NS, Makarenko AS, Tanchuk VY, Prokopenko VV. Virtual computational chemistry laboratory - design and description, J. Comput. Aid. Mol. Des. 2005, 19, 453-63
[28] Coutard, B., Valle, C., de Lamballerie, X., Canard, B., Seidah, N.G., and Decroly, E. (2020). The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 176, 104742.
[29] Park, J.E., Li, K., Barlan, A., Fehr, A.R., Perlman, S., McCray, P.B., Jr., and Gallagher, T. (2016). Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism. Proc. Natl. Acad. Sci. USA 113, 12262–12267.
[30] Wang, Q., Qiu, Y., Li, J.Y., Zhou, Z.J., Liao, C.H., and Ge, X.Y. (2020a). A unique protease cleavage site predicted in the spike protein of the novel pneumonia coronavirus (2019-nCoV) potentially related to viral transmissibility. Virol. Sin. 35, 337–339.
[31] Hoffmann, M., Kleine-Weber, H., and Po¨ hlmann, S. (2020a). A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol. Cell 78, 779–784.e5.
[32] Canrong Wu, Mengzhu Zheng, Yueying Yang, Xiaoxia Gu, Kaiyin Yang, Mingxue Li, Yang Liu, Qingzhe Zhang, Peng Zhang, Yali Wang, Qiqi Wang, Yang Xu, Yirong Zhou, Yonghui Zhang, Lixia Chen, and Hua Li. Furin: A Potential Therapeutic Target for COVID-19
iScience 23, 101642, October 23, 2020
[33] Zhijian Xu, Cheng Peng, Yulong Shi, Zhengdan Zhu, Kaijie Mu, Xiaoyu Wang, Weiliang Zhu. Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation. bioRxiv 2020.01.27.921627; doi: https://doi.org/10.1101/2020.01.27.921627
[34] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum in: Lancet. 2020 Jan 30;: PMID: 31986264; PMCID: PMC7159299.
[35] Dayer M R, Taleb-Gassabi S, Dayer M S. Lopinavir; A Potent Drug against Coronavirus Infection: Insight from Molecular Docking Study, Arch Clin Infect Dis. 2017 ; 12(4):e13823. doi: 10.5812/archcid.13823.
[36] Andrew J. Gross, Discovery of an Allosteric Site on Furin, Contributing to Potent Inhibition: A Promising Therapeutic for the Anemia of Chronic Inflammation. 2014. Brigham Young U, PhD dissertation.
[37] Gedikli MA, Tuzun B, Aktas A, Sayin K, Ataseven H. Are clarithromycin, azithromycin and their analogues effective in the treatment of COVID19? Bratisl Lek Listy. 2021;122(2):101-110. doi: 10.4149/BLL_2021_015. PMID: 33502877.
[38] Yacouba, A., Olowo-okere, A. & Yunusa, I. Repurposing of antibiotics for clinical management of COVID-19: a narrative review. Ann Clin Microbiol Antimicrob 20, 37 (2021). https://doi.org/10.1186/s12941-021-00444-9
[39] Dayer, M.R., Old Drugs for a Newly Emerging Viral Disease, COVID-19: Bioinformatic
Prospective. Organic Chemistry Research, 2021; 7(1): 12-22.
https://arxiv.org/abs/2003.04524
[40] Formiga FR, Leblanc R, de Souza Rebouças J, Farias LP, de Oliveira RN, Pena L. Ivermectin: an award-winning drug with expected antiviral activity against COVID-19. J Control Release. 2021 Jan 10;329:758-761. doi: 10.1016/j.jconrel.2020.10.009. Epub 2020 Oct 7. PMID: 33038449; PMCID: PMC7539925.
[41] Vallejos J, Zoni R, Bangher M, Villamandos S, Bobadilla A, Plano F, Campias C, Chaparro Campias E, Achinelli F, Guglielmone HA, Ojeda J, Medina F, Farizano Salazar D, Andino G, Ruiz Diaz NE, Kawerin P, Meza E, Dellamea S, Aquino A, Flores V, Martemucci CN, Vernengo MM, Martinez SM, Segovia JE, Aguirre MG. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial. Trials. 2020 Nov 24;21(1):965. doi: 10.1186/s13063-020-04813-1. PMID: 33234158; PMCID: PMC7683865.
[42] Hellwig MD, Maia A. A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin. Int J Antimicrob Agents. 2021 Jan;57(1):106248. doi: 10.1016/j.ijantimicag.2020.106248. Epub 2020 Nov 28. PMID: 33259913; PMCID: PMC7698683.